- Home
- AVD vs VTYX Comparison
AVD vs VTYX Comparison
Compare AVD & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- VTYX
- Stock Information
- Founded
- AVD 1969
- VTYX 2018
- Country
- AVD United States
- VTYX United States
- Employees
- AVD N/A
- VTYX N/A
- Industry
- AVD Agricultural Chemicals
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- AVD Industrials
- VTYX Health Care
- Exchange
- AVD Nasdaq
- VTYX Nasdaq
- Market Cap
- AVD 163.2M
- VTYX 154.9M
- IPO Year
- AVD N/A
- VTYX 2021
- Fundamental
- Price
- AVD $4.47
- VTYX $8.53
- Analyst Decision
- AVD Strong Buy
- VTYX Buy
- Analyst Count
- AVD 1
- VTYX 3
- Target Price
- AVD $12.00
- VTYX $12.50
- AVG Volume (30 Days)
- AVD 142.9K
- VTYX 9.7M
- Earning Date
- AVD 10-31-2025
- VTYX 11-06-2025
- Dividend Yield
- AVD N/A
- VTYX N/A
- EPS Growth
- AVD N/A
- VTYX N/A
- EPS
- AVD N/A
- VTYX N/A
- Revenue
- AVD $529,067,000.00
- VTYX N/A
- Revenue This Year
- AVD N/A
- VTYX N/A
- Revenue Next Year
- AVD $3.54
- VTYX N/A
- P/E Ratio
- AVD N/A
- VTYX N/A
- Revenue Growth
- AVD N/A
- VTYX N/A
- 52 Week Low
- AVD $3.28
- VTYX $0.78
- 52 Week High
- AVD $6.68
- VTYX $9.50
- Technical
- Relative Strength Index (RSI)
- AVD 29.57
- VTYX 82.53
- Support Level
- AVD $5.14
- VTYX $5.75
- Resistance Level
- AVD $5.45
- VTYX $7.50
- Average True Range (ATR)
- AVD 0.23
- VTYX 0.72
- MACD
- AVD -0.09
- VTYX 0.43
- Stochastic Oscillator
- AVD 6.67
- VTYX 84.07
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.